Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Cancer Lett ; 203(2): 225-31, 2004 Jan 20.
Article in English | MEDLINE | ID: mdl-14732231

ABSTRACT

Characterization of the molecular basis of tumor recognition by T cells has shown that major histocompatibility complex (MHC) class I molecules play a crucial role in presenting antigenic peptide epitopes to cytotoxic T lymphocytes. MHC class Ia downregulation has been repeatedly described on melanoma cells and is thought to be involved in the failure of the immune system to control tumor progression. Proper assembly of MHC class I molecules is dependent on several cofactors, e.g. the chaperones calnexin and calreticulin residing in the endoplasmic reticulum. Alterations in the expression of these chaperones may have important implications for MHC class I assembly, peptide loading, and presentation on the tumor cell surface and thus may contribute to the immune escape phenotype of tumor cells. In the present study, we compared melanoma lesions representing different stages of tumor progression with regard to the expression of calnexin and calreticulin in tumor cells by means of immunohistochemistry. Metastatic melanoma lesions exhibited significant downregulation of calnexin as compared to primary melanoma lesions. In contrast, chaperone calreticulin was expressed in melanoma cells of primary as well as of metastatic lesions. Our data suggest that chaperone-downregulation, particularly calnexin-downregulation, may contribute to the metastatic phenotype of melanoma cells in vivo. Consistently, conserved chaperone expression in metastatic melanoma lesions may be a useful criterion for selection of patients for treatment with T cell-based immunotherapies.


Subject(s)
Calnexin/biosynthesis , Calreticulin/biosynthesis , Down-Regulation , Endoplasmic Reticulum/metabolism , Gene Expression Regulation, Neoplastic , Melanoma/metabolism , Calnexin/genetics , Calreticulin/genetics , Disease Progression , Humans , Immunohistochemistry , Immunotherapy/methods , Melanoma/pathology , Neoplasm Metastasis , Phenotype , Skin Neoplasms/metabolism , T-Lymphocytes/metabolism
2.
Melanoma Res ; 13(3): 253-8, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12777979

ABSTRACT

Spontaneous regression of primary melanoma lesions is regarded as the result of the recognition of melanoma-associated antigen (MAA)-derived peptides by cytotoxic T-lymphocytes and destruction of melanoma cells. The transporter associated with antigen processing (TAP1/2) is likely to play a crucial role in this process since it loads antigen peptides onto MHC class I molecules. To determine the impact of TAP defects on the spontaneous regression of melanoma lesions, we have compared the expression of TAP1 and TAP2 in 39 primary melanoma lesions exhibiting clinical and histological signs of tumour regression and in 35 primary melanoma lesions without regression phenomena. TAP1 expression was significantly associated with regression of melanoma lesions, since the staining pattern with anti-TAP1 antibody was positive in 38 of the 39 lesions exhibiting regression phenomena and in only 24 of the 35 lesions without histopathological signs of tumour regression. In the latter group, six lesions were stained with a heterogeneous pattern and five with a negative pattern. Furthermore, in lesions with a heterogeneous staining pattern, a clear association was found between TAP1 expression in melanoma cells and the presence of tumour-infiltrating lymphocytes. These results suggest that TAP1 plays an important role in the MAA-specific cytotoxic T-lymphocyte response, which has been suggested to underlie the spontaneous regression of primary melanoma.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Gene Expression Regulation, Neoplastic/physiology , Melanoma/metabolism , Skin Neoplasms/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 2 , ATP Binding Cassette Transporter, Subfamily B, Member 3 , Antigens, Neoplasm , Down-Regulation , Humans , Melanoma/pathology , Melanoma-Specific Antigens , Neoplasm Proteins/metabolism , Remission, Spontaneous , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...